A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause.
Nurs Womens Health
; 28(1): 80-84, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-38161058
ABSTRACT
Vasomotor symptoms of menopause, more commonly called hot flashes and night sweats, affect up to 80% of individuals going through the menopausal transition. Hormone therapy with estrogen and often progesterone is the most effective treatment for these symptoms. Many people, however, cannot take estrogen or do not want to take hormones. Many individuals seek nonhormonal, over-the-counter treatment options that have little safety and efficacy information to support their use. In March 2023, the U.S. Food and Drug Administration approved fezolinetant (Veozah), a neurokinin 3 receptor antagonist for the treatment of vasomotor symptoms of menopause. This article presents an overview of fezolinetant, including appropriate usage, adverse effects, its use in special populations, and implications for nursing practice.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tiadiazoles
/
Menopausia
/
Compuestos Heterocíclicos con 2 Anillos
Límite:
Female
/
Humans
Idioma:
En
Revista:
Nurs Womens Health
Asunto de la revista:
ENFERMAGEM
/
OBSTETRICIA
/
PERINATOLOGIA
/
SAUDE DA MULHER
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos